MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome
Jennifer A. Byrne(The University of Sydney), Philippa M. O’Brien(Garvan Institute of Medical Research), Anna DeFazio(The University of Sydney), Neville F. Hacker(New South Wales Department of Health), Rajmohan Murali(Memorial Sloan Kettering Cancer Center), Jayne Hardy(Children's Hospital at Westmead), James Scurry, Catherine Emmanuel(Peter MacCallum Cancer Centre), Sanaz Maleki(Garvan Institute of Medical Research), Susan Fanayan(The University of Sydney), Robert L. Sutherland(Garvan Institute of Medical Research), Brian Gloss(Garvan Institute of Medical Research)
Cited by 64
Related Papers
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Driver mutations in <i>TP53</i> are ubiquitous in high grade serous carcinoma of the ovary
|The Journal of Pathology|2010|836
Mutation of <i>FOXL2</i> in Granulosa-Cell Tumors of the Ovary
|New England Journal of Medicine|2009|775
Germline mutations in BAP1 predispose to melanocytic tumors
|Nature Genetics|2011|724